A Phase 4 interventional study of Oxymetazoline 0.1% (Upneeq) and Brimonidine 0.025% (Lumify) in Acquired Ptosis, sponsored by Duke University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Duke University · Phase 4, Interventional, and Treatment
This study aims to compare the short-term effect of oxymetazoline 0.1% (Upneeq) versus brimonidine 0.025% (Lumify) on upper-eyelid position in adults with acquired ptosis. Participants will undergo standardized eyelid photography, receive a single dose of either Upneeq or Lumify in randomized order, and have repeat photographs approximately 60 minutes later. They will return for a second visit to receive the alternate medication using the same procedures. Eyelid height measurements will be obtained from coded images by masked graders. Data will be analyzed using paired statistical methods appropriate for a crossover design. Both medications are FDA-approved topical ophthalmic drops, and the study involves minimal risk with anticipated transient ocular irritation as the most common adverse event.
Exclusion Criteria:
Participants receive oxymetazoline 0.1% (Upneeq) at Visit 1 and brimonidine 0.025% (Lumify) at Visit 2.
Drug: Oxymetazoline 0.1% (Upneeq) · Drug: Brimonidine 0.025% (Lumify)
Participants receive brimonidine 0.025% (Lumify) at Visit 1 and oxymetazoline 0.1% (Upneeq) at Visit 2.
Drug: Oxymetazoline 0.1% (Upneeq) · Drug: Brimonidine 0.025% (Lumify)
Single instillation of oxymetazoline 0.1% ophthalmic solution in both eyes.
Single instillation of brimonidine 0.025% ophthalmic solution in both eyes.
Change in upper-eyelid height (MRD1) (Upneeq vs. Lumify)
Change in MRD1 at \~60 minutes after drop instillation (Upneeq vs. Lumify)
Time frame: 60 minutes after instillation
Change in palpebral fissure height (PFH)
Time frame: 60 minutes after instillation
Number of participants with Conjunctival redness
Time frame: 60 minutes after each medication
Participant-reported improvement in eyelid elevation or visual function
Participants will report eyelid elevation and visual function on a 0-10 numeric rating scale after each medication, where: 0 = no noticeable eyelid lift and 10 = maximal eyelid lift. For visual function: 0 = no improvement in vision and 10 = maximal improvement in vision.
Time frame: 60 minutes after each medication
Frequency of Adverse Events
Assess the safety and tolerability of a single dose of Upneeq and Lumify.
Time frame: 60 minutes after each medication
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Duke University